Replies to post #288033 on Avid Bioservices Inc (CDMO)

[cjgaddy]

Neato: H.McArthur/CedSinai, D.Page/ProvCC => MBC Advisors for PPHM

Nov2016: “Immunotherapy for the Treatment of Breast Cancer: Checkpoint Blockade, Cancer Vaccines, and Future Directions in Combination Immunotherapy”
Clinical Advances in Hematology & Oncology
Authors(equal contributors):
* Heather L. McArthur MD/MPH: Medical Director of Breast Oncology at Cedars Sinai Medical Ctr, Los Angeles
* David B. Page MD: Oncologist at the Providence Cancer Ctr and a researcher at the Earle A. Chiles Res. Inst., Portland
DISCLOSURES:
* Dr H.McArthur has participated in advisory boards for Celgene, Merck, Spectrum Pharm., OBI Pharma, Peregrine Pharmaceuticals, Syndax Pharm, and has received research support from Bristol-Myers Squibb, MedImmune/AstraZeneca, Eli Lilly, Ziopharm Oncology, Merck.
* Dr D.Page has participated in advisory boards for Celgene and Peregrine Pharmaceuticals, and has received research support from MedImmune and Merck.
http://www.hematologyandoncology.net/index.php/archives/november-2016/immunotherapy-for-the-treatment-of-breast-cancer-checkpoint-blockade-cancer-vaccines-and-future-directions-in-combination-immunotherapy

= = = = = = = = = = = = = = = = = = = = = = = = = =
1-11-16 PR, “Peregrine Provides Update on Planned Expansion of Bavi Clinical Pgm in Lung, Breast and Other Cancers”… http://tinyurl.com/zhdy37a
PLANNED TRIALS...
#4. Phase II Trial in Early Stage TNBC in Combination with Chemotherapy
Peregrine is planning to initiate a Phase II trial of bavituximab in combination with neoadjuvant chemotherapy in early stage TNBC. The primary endpoint of this study is to determine the pathologic complete response rate (pCR), an accepted surrogate endpoint in early stage TNBC. The concept for this neoadjuvant setting trial, which will be conducted at a few select U.S. sites, originated from Peregrine's ongoing collaboration with Memorial Sloan Kettering Cancer Center (MSKCC). The company has filed a study protocol to its existing bavituximab IND application in the U.S. and is currently working to open clinical trial sites, including one that will be led by David B. Page, M.D., at the Providence Cancer Center in Oregon. http://tinyurl.com/zhdy37a
- - - - - - - -DR. DAVID PAGE: note his prior work with Dr. Jedd Wolchok, chief of Mem.Sloan's Melanoma & Immunotherapeutics Service who “investigates novel approaches for cancer immunotherapy and mechanisms of tumor cell–immune cell interactions”… http://www.bcrfcure.org/researchers/david-page

= = = = = = = = = = = = = =
Cedars-Sinai Researcher Dr. Heather McArthur (Medical Director, Breast Oncology) lists PPHM in her Disclosures in this Joint Mem.Sloan/Cedars-Sinai AACR’17 Abstract, where she’s the Lead Author, along with co-authors Jedd Wolchok, Taha Merghoub, and several other Mem. Sloan researchers. So, 2 of Dr. Wolchok’s 5 AACR’17 abstracts are Joint PPHM+MemSloan, and a 3rd is Joint CedarsSinai+MemSloan whereby the Lead Author lists Peregrine in her disclosures. Maybe we need to add Cedars-Sinai to our collabs list along with Memorial Sloan Kettering, Duke, MDA, Rutgers, ImmunoVaccine, and UTSW.
SEE: 3-1-17: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129115855

= = = = = = = = = = = = = = = = = = = = = =
BAVI MOA 10-22-16: Duke’s Herbert K. Lyerly & PPHM poster on AntiPS/TNBC data at AACR’s Tumor Immunotherapy Conf./Boston http://tinyurl.com/zzryfok
...”Title: ‘Modulating The Tumor Microenvironment to Enhance Cancer Immunotherapy by Inducing Phosphatidylserine Expression on the Tumor Surface”’… Data showed that a combination of anti-PS & anti-PD-L1 therapies, with or without paclitaxel, led to greater anti-tumor responses than any of the treatments administered as single agents or dual treatment combinations w/paclitaxel, in the E0771 murine model of TNBC.”
Kensuke Kaneko 1, Takuya Osada 1, Bruce D. Freimark 2, Herbert Kim Lyerly ** (Duke Univ.)
1=Duke University, Durham, NC
2=Peregrine Pharmaceuticals, Inc.
**Dr. Herbert Kim Lyerly: https://immunology.duke.edu/people/herbert-kim-lyerly-md (George Barth Geller Professor, Duke Univ. MC)
PPHM’s Dr. Jeff Hutchins 10-24-16: “We plan to continue to work with our collaborators at Duke Univ. Medical Center to further study the therapeutic potential of PS-targeting agents in combination with checkpoint inhibitors like anti-PD-L1 and conventional therapies that augment immunotherapy mechanisms."